These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7180577)

  • 1. Drug-induced neutropenia--a survey for Stockholm 1973-1978.
    Arneborn P; Palmblad J
    Acta Med Scand; 1982; 212(5):289-92. PubMed ID: 7180577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-induced neutropenia in the Stockholm region 1973-75: frequency and causes.
    Arneborn P; Palmblad J
    Acta Med Scand; 1978; 204(4):283-6. PubMed ID: 80921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-induced neutropenias in the Stockholm region 1976-1977.
    Arneborn P; Palmblad J
    Acta Med Scand; 1979; 206(4):241-3. PubMed ID: 92166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-associated agranulocytosis: 20 years of reporting in The Netherlands (1974-1994).
    van der Klauw MM; Wilson JH; Stricker BH
    Am J Hematol; 1998 Mar; 57(3):206-11. PubMed ID: 9495370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-induced neutropenia.
    Lancet; 1983 Apr; 1(8329):857-8. PubMed ID: 6132184
    [No Abstract]   [Full Text] [Related]  

  • 6. Pediatric drug safety signal detection of non-chemotherapy drug-induced neutropenia and agranulocytosis using electronic healthcare records.
    Wei R; Jia LL; Yu YC; Nie XL; Song ZY; Fan DF; Xie YF; Peng XX; Zhao ZG; Wang XL
    Expert Opin Drug Saf; 2019 May; 18(5):435-441. PubMed ID: 31002530
    [No Abstract]   [Full Text] [Related]  

  • 7. Neutropenia and agranulocytosis in England and Wales: incidence and risk factors.
    van Staa TP; Boulton F; Cooper C; Hagenbeek A; Inskip H; Leufkens HG
    Am J Hematol; 2003 Apr; 72(4):248-54. PubMed ID: 12666135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization pattern of metamizole in northern Sweden and risk estimates of agranulocytosis.
    Bäckström M; Hägg S; Mjörndal T; Dahlqvist R
    Pharmacoepidemiol Drug Saf; 2002; 11(3):239-45. PubMed ID: 12051124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole).
    Hedenmalm K; Spigset O
    Eur J Clin Pharmacol; 2002 Jul; 58(4):265-74. PubMed ID: 12136373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metamizole and the risk of drug-induced agranulocytosis and neutropenia in statutory health insurance data.
    Klose S; Pflock R; König IR; Linder R; Schwaninger M
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Apr; 393(4):681-690. PubMed ID: 31811328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mebhydrolin napadisylate. A possible cause of reversible agranulocytosis and neutropenia.
    McEwen J; Strickland WJ
    Med J Aust; 1982 Nov; 2(11):523-5. PubMed ID: 6130466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term patient monitoring for clozapine-induced agranulocytosis and neutropenia in Korea: when is it safe to discontinue CPMS?
    Kang BJ; Cho MJ; Oh JT; Lee Y; Chae BJ; Ko J
    Hum Psychopharmacol; 2006 Aug; 21(6):387-91. PubMed ID: 16933201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metamizole-associated neutropenia: Comparison of patients with neutropenia and metamizole-tolerant patients.
    Rudin D; Spoendlin J; Cismaru AL; Liakoni E; Bonadies N; Amstutz U; Meier CR; Krähenbühl S; Haschke M
    Eur J Intern Med; 2019 Oct; 68():36-43. PubMed ID: 31383393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recognition and management of drug-induced blood cytopenias: the example of drug-induced acute neutropenia and agranulocytosis.
    Andrès E; Federici L; Weitten T; Vogel T; Alt M
    Expert Opin Drug Saf; 2008 Jul; 7(4):481-9. PubMed ID: 18613811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse Drug Reactions Advisory Committee: ADRAC report for 1980.
    Med J Aust; 1982 May; 1(10):416-9. PubMed ID: 6808324
    [No Abstract]   [Full Text] [Related]  

  • 16. Causes of agranulocytosis in a hospital population: identification of dipyrone as an important causative agent.
    Shinar E; Hershko C
    Isr J Med Sci; 1983 Mar; 19(3):225-9. PubMed ID: 6853118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonchemotherapy drug-induced neutropenia and agranulocytosis: could medications be the culprit?
    Pick AM; Nystrom KK
    J Pharm Pract; 2014 Oct; 27(5):447-52. PubMed ID: 25124379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis.
    Elalfy M; Wali YA; Qari M; Al Damanhouri G; Al-Tonbary Y; Yazman D; Al Hawsawi Z; Karakas Z; Kilinc Y; Yesilipek MA; Badr M; Elsafy U; Salama M; Abdel Rahman Y; Shebl S; Stilman A; Toiber Temin N; Tricta F
    Pediatr Blood Cancer; 2014 May; 61(5):879-84. PubMed ID: 24376176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A possible increased risk of metamizole-associated neutropenia among COVID-19 patients.
    Lerman TT; Sagi M; Shafir Y; Sheena L; Cohen E; Goldberg E; Krause I
    Br J Clin Pharmacol; 2021 Jul; 87(7):2902-2906. PubMed ID: 33332642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-induced agranulocytosis in the Berlin case-control surveillance study.
    Huber M; Andersohn F; Bronder E; Klimpel A; Thomae M; Konzen C; Meyer O; Salama A; Schrezenmeier H; Hildebrandt M; Späth-Schwalbe E; Grüneisen A; Kreutz R; Garbe E
    Eur J Clin Pharmacol; 2014 Mar; 70(3):339-45. PubMed ID: 24297345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.